In vivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane

Journal of Immunology

Volumn 175, Issue 11, 2005, Pages 7763-7770

  Spitzer, Dirk ^a   Unsinger, Jacqueline ^a   Mao, Dailing ^a   Wu, Xiaobo ^a   Molina, Hector ^a   Atkinson, John P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT REGULATORY PROTEIN; PROTEIN CRRY; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT INHIBITION; CONTROLLED STUDY; ERYTHROCYTE LIFESPAN; ERYTHROCYTE MEMBRANE; ERYTHROCYTE TRANSFUSION; HALF LIFE TIME; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 28244463961     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.11.7763     Document Type: Article

References (54)

1. Walport, M. J. 2001. Complement: first of two parts. N. Engl. J. Med. 344: 1058-1066.
2. Walport, M. J. 2001. Complement: second of two parts. N. Engl. J. Med. 344: 1140-1144.
3. Morgan, B. P., and C. L. Harris. 1999. Regulation in the activation pathways. In Complement Regulatory Proteins. Harcourt Brace, San Diego, pp. 41-120.
4. Liszewski, M. K., T. C. Farries, D. M. Lublin, I. A. Rooney, and J. P. Atkinson. 1996. Control of the complement system. Adv. Immunol. 61: 201-283.
5. Richards, A., E. J. Kemp, M. K. Liszewski, J. A. Goodship, A. K. Lampe, R. Decorte, M. H. Muslumanolu, S. Kavukcu, G. Filler, Y. Pirson, et al. 2003. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. USA 100: 12966-12971.
6. Goodship, T. H. J., M. K. Liszewski, E. J. Kemp, A. Richards, and J. P. Atkinson. 2004. Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends Mol. Med. 10: 226-231.
7. Takeda, J., T. Miyata, K. Kawagoe, Y. Iida, Y. Endo, T. Fujita, M. Takahashi, T. Kitani, and T. Kinoshita. 1993. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal haemoglobinuria. Cell 73: 703-711.
8. Rosse, W. F. 1997. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine 76: 63-93.
9. Dacie, J. V., and L. Luzzatto. 1996. Paroxysmal nocturnal haemoglobinuria. In Oxford Textbook of Medicine, Vol. 3. D. J. Wetherall, A. Warrel, and L. Ledigham, eds. Oxford University Press, Oxford, pp. 3449-3452.
10. Atkinson, J. P., and M. Bessler. 2000. Paroxysmal nocturnal hemoglobinuria. In The Molecular Basis of Blood Disease. G. Stamatoyannopoulos, P. W. Majerus, R. M. Perlmutter, and H. Varmus, eds. Saunders, Philadelphia, pp. 564-577.
11. Parker, C. J. 2002. Historical aspects of paroxysmal nocturnal haemoglobinuria: defining the disease. Br. J. Haematol. 117: 3-22.
12. Nakano, Y., K. Sumida, N. Kikuta, N. H. Murira, T. Tobe, and M. Tomita. 1992. Complete determination of disulfide bonds localized within the short consensus repeat units of decay accelerating factor (CD55 antigen). Biochem. Biophys. Acta 1116: 235-240.
13. Lublin, D. M., J. Krsek-Staples, M. K. Pangburn, and J. P. Atkinson. 1986. Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor. J. Immunol. 137: 1629-1635.
14. Lublin, D. M., and J. P. Atkinson. 1989. Decay accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7: 35-58.
15. Coyne, K. E., S. E. Hall, E. S. Thompson, M. A. Arce, T. Kinoshita. T. Fujita, D. J. Anstee, W. Rosse, and D. M. Lublin. 1992. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149: 2906-2913.
16. Medof, M. E., E. T. Walter, W. L. Roberts, R. Haas, and T. L. Rosenberry. 1986. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochem. 25: 6740-6747.
17. Spicer, A. P., M. F. Seldin, and S. J. Gendler. 1995. Molecular cloning-and chromosomal localization of the mouse decay-accelerating factor (DAF) genes: duplicated genes encode GPI-anchored and transmembrane forms. J. Immunol. 155: 3079-3091.
18. Nicholson-Weller, A., J. P. March, S. I. Rosenfeld, and K. F. Austen. 1983. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci. USA 80: 5066-5070.
19. Pangburn, M. K., R. D. Schreiber, and H. J. Muller-Eberhard. 1983. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc. Natl. Acad. Sci. USA 80: 5430-5434.
20. Sun, X., C. D. Funk, C. Deng, A. Sahu, J. D. Lambris, and W. C. Song. 1999. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc. Natl. Acad. Sci. USA 96: 628-633.
21. Harris, C. L., N. K. Rushmere, and B. P. Morgan. 1999. Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem. J. 341: 821-829.
22. Davies, A., G. Simmons, R. A. Hale, H. Harrison, H. Tighe, P. J. Lachmann, and H. Waldmann. 1989. CD59, an LY6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170: 637.
23. Meri, S., B. P. Morgan, A. Davies, R. H. Daniels, M. G. Olavesen, H. Waldmann, and P. J. Lachmann. 1990. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1-9.
24. Powell, M. B., K. J. Marchbank, N. K. Rushmere, C. W. Van Den Berg, and B. P. Morgan. 1997. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J. Immunol. 158: 1692.
25. Ahearn, J. M., and D. T. Fearon. 1989. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv. Immunol. 46: 183-219.
26. Klickstein, L. B., T. J. Bartow, V. Miletic, L. D. Rabson, J. A. Smith, and D. T. Fearon. 1988. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168: 1699-1717.
27. Krych, M., L. Clemenza, D. Howdeshell, R. Hauhart, D. Hourcade, and J. P. Atkinson. 1994. Analysis of the functional domains of complement receptor type I (C3b/C4b receptor: CD35) by substitution mutagenesis. J. Biol. Chem. 269: 13273-13278.
28. Krych-Goldberg, M., and J. P. Atkinson. 2001. Structure function relationships of complement receptor type 1. Immunol. Rev. 180: 112-122.
29. Molina, H. 2002. The murine complement regulator Crry: new insights into the immunobiology of complement regulation. Cell Mol. Life Sci. 59: 220-229.
30. Miwa, T., L. Zhou, B. Milliard, H. Molina, and W. C. Song. 2002. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood 99: 3707-3716.
31. Molina, H., T. Miwa, L. Zhou, B. Hilliard, D. Mastellos, M. A. Maldonado, J. D. Lambris, and W. C. Song. 2002. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Blood 100: 4544-4549.
32. Song, H., C. He, C. Knaak, J. M. Guthridge, V. M. Holers, and S. Tomlinson. 2003. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J. Clin. Invest. 111: 1875-1885.
33. Moran, P., H. Beasley, A. Gorrell, E. Martin, P. Gribling, H. Fuchs, N. Gillett, L. E. Burton, and I. W. Caras. 1992. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J. Immunol. 149: 1736-1743.
34. Rittershaus, C. W., L. J. Thomas, D. P. Miller, M. D. Picard, K. M. Geoghegan-Barek, S. M. Scesney, L. D. Henry, A. C. Sen, A. M. Bertino, G. Hannig, et al. 1999. Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J. Biol. Chem. 274: 11237-11244.
35. Limon, S. M., A. S. Williams, I. Dodd, R. Smith, B. D. Williams, and B. P. Morgan. 2000. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum. 43: 2590-2597.
36. Zhang, H., S. Lu, S. L. Morrison, and S. Tomlinson. 2001. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J. Biol. Chem. 276: 27290.
37. Kina, T., K. Ikuta, E. Takayama, K. Wada, A. S. Majumdar, I. L. Weissman, and Y. Katsura. 2000. The monoclonal antibody TER-119 recognizes a molecular associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br. J. Haematol. 109: 280.
38. Auffray, I., S. Marfatia, K. de Jong, G. Lee, C.-H. Huang, C. Paszty, M. J. A. Tanner, N. Mohandas, and J. A. Chasis. 2001. Glycophorin A dimerization and band 3 interaction during erythroid membrane biogenesis: in vivo studies in human glycophorin A transgenic mice. Blood 97: 2872-2878.
39. Spitzer, D., J. Unsinger, M. Bessler, and J. P. Atkinson. 2004. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol. Immunol. 40:911-919.
40. Xu, C., D. Mao, V. M. Holers, B. Palanca, A. M. Cheng, and H. Molina. 2000. A critical role for the murine complement regulator Crry in fetomaternal tolerance. Science 287: 498-501.
41. Dirks, W., M. Wirth, and H. Hauser. 1993. Dicistronic transcription units for gene expression in mammalian cells. Gene 128: 247.
42. Aegerter-Shaw, M., J. L. Cole, L. B. Klickstein, W. W. Wong, D. T. Fearon, P. A. Lalley, and J. H. Weis. 1987. Expansion of the complement receptor gene family: identification in the mouse of two new genes related to the CR1 and CR2 gene family. J. Immunol. 138: 3488-3494.
43. Paul, M. S., M. Aegerter, S. E. O'Brien, C. B. Kurtz, and J. H. Weis. 1989. The murine complement receptor gene family: analysis of mCRY gene products and their homology to human CR1. J. Immunol. 142: 582-589.
44. Spitzer, D., H. Hauser, and D. Wirth. 1999. Complement-protected amphotropic retroviruses from murine packaging cells. Hum. Gene Ther. 10: 1893.
45. Spitzer, D., K. E. Dittmar, M. Rohde, H. Hauser, and D. Wirth. 2003. Green fluorescent protein-tagged retroviral envelope protein for analysis of virus-cell interactions. J. Virol. 77: 6070-6075.
46. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680.
47. Magnani, M., L. Rossi, V. Stocchi, L. Cucchiarini, G. Piacentini, and G. Fornaini. 1988. Effect of age on some properties of mice erythrocytes. Mech. Ageing Dev. 42: 37-47.
48. Nielsen, P. J., B. Lorenz, A. M. Muller, R. H. Wenger, F. Brombacher, M. Simon, T. von der Weid, W. J. Langhorne, H. Mossmann, and G. Kohler. 1997. Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice. Blood 89: 1058.
49. Bormann, B. J., W. J. Knowles, and V. T. Marchesi. 1989. Synthetic peptides mimic the assembly of transmembrane glycoproteins. J. Biol. Chem. 264: 4033-4037.
50. Furthmayr, H., and V. T. Marchesi. 1976. Subunit structure of human erythrocyte glycophorin A. Biochemistry 15: 1137-1144.
51. Chasis, J., P. Agre, and N. Mohandas. 1988. Decreased membrane mechanical stability and in vivo loss of surface area reflect spectrin deficiencies in hereditary spherocytosis. J. Clin. Invest. 82: 617-623.
52. Hoogenboom, H. R. 2002. Overview of antibody phage-display technology and its applications. Methods Mol. Biol. 178: 1-37.
53. Mendez, M. J., L. L. Green, J. R. Corvalan, X. C. Jia, C. E. Maynard-Currie, X. D. Yang, M. L. Gallo, D. M. Louie, D. V. Lee, K. L. Erickson, et al. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. [Published erratum appears in 1997 Nat. Genet. 16: 410.] Nat. Genet. 15: 146-156.
54. Green, L. L. 1999. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231: 11-23.